Association Between AMH Levels and Fertility/Reproductive Outcomes Among Women Undergoing IVF: A Retrospective Study

Asha Srinivasan Vijay 1*, Murali Mohan Reddy Gopireddy 2*, Syed Fyzullah 3, Priyanka Gollapalli 2, M Maheswari 4, Usha Rani 3, Swathi Rajesh 3

1- Scientific Director and Dean, GarbhaGudi Institute of Reproductive Health and Research (GGIRHR), Hanumanthnagar, Bangalore, India
2- Evidence Generation, Evidencer Research Associates, Bangalore, India
3- Department of Embryology, GarbhaGudi Institute of Reproductive Health and Research (GGIRHR), Hanumanthnagar, Bangalore, India
4- Department of Reproductive Medicine, GarbhaGudi Institute of Reproductive Health and Research (GGIRHR), Hanumanthnagar, Bangalore, India

# The first and the second authors have had equal contribution to this manuscript

Abstract

Background: Anti-mullerian hormone (AMH) is a marker for predicting ovarian response to gonadotropin stimulation. It plays an important role in ovarian primordial follicle recruitment and dominant follicle selection. Therefore, the present study evaluated the AMH levels and their association with fertility/reproductive outcomes among women undergoing IVF.

Methods: A retrospective study was conducted on 665 women in GarbhaGudi Institute of Reproductive Health and Research in India from October 2018 to 2019. Subjects were divided into ≥1.1 and ≤1.1 AMH level groups. Data on age, luteinizing hormone (LH); LH (mIU/L), follicle-stimulating hormone values (FSH (mIU/ml)), LH value, oocytes retrieved, and oocytes fertilization were collected. AMH category was considered as the primary explanatory variable. Independent sample t-test and chi-square tests were performed. The p<0.05 was considered statistically significant.

Results: Couple’s age, FSH values (mIU/ml), number of large follicles, matured oocytes, fertilized oocytes, and cleaved embryos were statistically significant (p<0.001) among subjects with ≥1.1 AMH values. Percentage of women with successful embryo transfer was slightly higher among AMH category 1.1 (p=0.09). Fertilization rate (86.67±20.08 vs. 83.64±21.39, p=0.18) and clinical pregnancy rate (43.38% vs. 36.36%, p=0.19) were slightly higher among women with AMH level of ≥1.1 as compared to AMH of <1.1. Live birth rate was slightly higher among women with AMH level of 1.1 (25.85% vs. 22.22%, p=0.45). Also, the number of fertilized oocytes was associated with clinical pregnancy rate (aOR=1.20, 95%CI 1.09-1.33).

Conclusion: Women with ≥1.10 serum AMH levels had more number of retrieved oocytes, good oocyte quality, increased embryo transfer, and fertilization rates.

Keywords: Anti-mullerian hormone, Fertilization, Pregnancy rate.

To cite this article: Vijay AS, Gopireddy MMR, Fyzullah S, Gollapalli P, Maheswari M, Rani U, et al. Association Between AMH Levels and Fertility/Reproductive Outcomes Among Women Undergoing IVF: A Retrospective Study. J Reprod Infertil. 2022;23(1):54-60. http://dx.doi.org/10.18502/jri.v23i1.8453.

Introduction

Conventionally, embryo morphology was used as a guideline for embryo selection, and other methods include oocyte and zygote morphology, blastocyst culture, and blastomere symmetry (1). Serum levels of many important key hormones are used to monitor the growth of the
gonadotropin-stimulated follicle and ovarian reserve in assisted reproductive technology (ART). Measurement of basal serum hormone concentrations such as luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, inhibin, and ultrasonographic indices on the third day of the cycle such as several early antral follicles and pretreatment ovarian volume were used as classic methods to predict the response of ovarian stimulation (2). Recently, anti-mullerian hormone (AMH) has been proposed for predicting ovarian response to gonadotropin stimulation.

AMH is a dimeric glycoprotein that belongs to the transforming growth factor β (TGF β) superfamily (3). AMH expression was first noted in the proliferating granulosa cells in primary follicles of the ovary with the greatest levels of expression in pre-antral and early antral follicles and the concentrations gradually fall in mural granulosa cells of large antral follicles (4). It was proposed that the size of the growing small follicles reflects the serum AMH concentrations, which in turn correlated with the ovarian reserve or the number of residual primordial follicles. Several investigators have observed a fall in serum AMH with increasing age, reflecting a drop in the number of growing follicles available for recruitment (5, 6). This fall in AMH precedes the fall observed in more traditional markers of ovarian reserve such as FSH and inhibin B. Poor response was observed in serum AMH levels of <1 ng/ml, the normal response in 1–4 ng/ml, and good response in >4 ng/ml (7).

According to previous studies, Irez et al. (8) reported that pregnancy rate (PR) was minimum in subjects with low AMH values <10% (9.5%) (p=0.040) and AMH levels may predict the presence of post maturity and nucleoli Z score, quality of oocytes, early cleavage and ICSI outcomes. Lekamge et al. (9) proposed that patients had lower fertilization rates, fewer oocytes, fewer embryos, and had a higher incidence of miscarriage with low AMH levels. Nardo et al. (10) reported that the AMH area under the receiver operating characteristic curve (ROC AUC) value of 0.81 was a good predictor of excessive response to ovarian stimulation.

Measurement of anti-mullerian hormone is a reliable predictor of in vitro fertilization (IVF) outcomes. It is a more precise measure of the ovarian reserve than the serum levels of hormones such as FSH, LH, and estrogen (E2). There is only limited research available in India that conducted retro-
spectively to evaluate the basal AMH levels accurately in order to reflect the total developing follicular cohort and ovarian response to gonadotropins in ART cycles. The present study was carried out to assess the AMH levels, and its association with oocyte morphology, embryo quality, cleavage rate, clinical pregnancy rate, and fertility outcome among women undergoing IVF.

**Methods**

A retrospective study was conducted in the department of embryology in the GarbhaGudi Institute of Reproductive Health and Research in Bangalore, India for a period of one year from October 2018 to October 2019 among women undergoing IVF cycles. Women <40 years of age, with both ovaries present on transvaginal ultrasound scan, no previous history of ovarian surgery, no exposure to cytotoxic drugs or pelvic radiation therapy, no hormonal therapy in the six months before entering the study, and body mass index ≥19 <30 kg/m² were included in the study.

Women with a history of previous IVF failure, donated sperm or oocyte, endometriosis, recurrent abortion, immune diseases, uterine abnormality, ovarian cyst or previous ovarian surgery, and allergy or contraindications to oral estradiol or progesterone treatment were excluded from the study. A priori sample size calculation was done with 665 samples. AMH measurement was performed in a single accredited laboratory situated within the study setting, considering the retrospective nature of the study. But as per the study findings, the ratio of the study participants in high and low AMH groups was 4.40. With the observed mean and standard deviation of the number of mature oocytes in the study and alpha error of 0.05, the study had yielded more than 99% power.

Outcome and explanatory variables in the study were considered to compile the different statistics. The p<0.05 was considered statistically significant. A daily dose of recombinant FSH (Gonal-F, Merck Serono, Germany), Folisure (Intas Pharmaceuticals Ltd, India), Briogyn (Cadila Healthcare Ltd, India), hMG (Menopur, Ferring Pharmaceuticals Ltd, India), hMG (Menopur, Ferring Pharmaceuticals, USA), Zyhm (Zydus Takeda Healthcare Ltd, India), and antagonist cetrorelix (Merck Serono, Germany) was given for controlled ovarian stimulation. The medicine used to prevent early LH surge is Ovucet (German Remedies, India) and leuprolide (Lupron Depot) in antagonist protocol and in GnRH agonist protocol, respectively.

The oocytes were collected through transvaginal
ultrasound-guided ovum pick-up at 35/34 hr after hCG administration. Before the removal of cumulus cells, the retrieved oocytes were kept in a culture medium for 2 to 3 hr. After exposure to a HEPES-buffered medium containing hyaluronidase, the surrounding cumulus cells were separated. For ICSI, mature oocytes releasing the first polar body were used. In evaluating embryo quality, the embryos were graded from day one until day five. Fertilization was affirmed by the presence of two pronuclei and the extrusion of the second polar body approximately 16-18 hr after ICSI.

The data was collected about couple’s age and BMI, LH (mIU/L), prolactin (PRL, ng/ml), FSH values (mIU/ml), large follicles, LH value on the day of hCG (ng/ml), retrieved oocytes, matured oocytes, fertilized oocytes, and cleaved embryos between AMH categories. Waiver of the participants’ consent in utilizing the data for the study was obtained from the ethics committee, and the study was approved by them (No: GEC/ GGISRH19_8/26052020, dated: 26.5. 2020).

AMH category was considered as the primary explanatory variable. Clinical pregnancy, fertilization rate, live birth rate, abortion rate, and biochemical pregnancy rate were outcome variables. Independent sample T-test was used for comparison of continuous outcome parameters with binary explanatory variables. The chi-square test was used for comparison of qualitative explanatory and outcome parameters. SPSS vs. 22 (IBM, USA) was used for statistical analysis. The p<0.05 was considered statistically significant.

Binary logistic regression with stepwise backward elimination was performed to build the optimal model to assess the determinants of clinical pregnancy. The model with the lowest Akaike Information Criterion (AIC) was considered the optimal model. AIC is a single number score that can be used to determine which of the multiple models is most likely to be the best for a given dataset. When AIC value is lower, better model can be selected. At the beginning, a total of 12 predictors were entered, making it a complete model, and at each step, one predictor was removed that lowered the AIC value the most. This procedure was stopped when the AIC value could not be lowered with the removal of any predictor.

**Results**

The mean baseline parameters like couple’s age and FSH values (mIU/ml) were found significantly higher in the AMH category <1.10 whereas parameters like large follicles, matured oocytes, oocytes fertilized and cleaved embryos were found significantly higher in the AMH category ≥1.10 (Table 1).

| Parameters                                      | AMH category (Mean±SD) | p-value |
|------------------------------------------------|------------------------|---------|
|                                                | <1.10 (n=123)          | ≥1.10 (n=542) |
| Wife’s age (year)                              | 34.3±5.53              | 30.2±4.48     | <0.001 |
| Husband’s age (year)                           | 38.3±5.28              | 35.4±5.68     | <0.001 |
| BMI of wife (kg/m²)                            | 27.4±5.3               | 26.3±4.7      | 0.036  |
| BMI of husband                                 | 27.0±4.25              | 27.2±4.21     | 0.629  |
| LH (mIU/L)                                     | 4.18±4.03              | 4.39±4.12     | 0.599  |
| PRL (ng/ml)                                    | 16.3±4.03              | 16.9±4.15     | 0.529  |
| FSH (mIU/ml)                                   | 10.3±4.52              | 5.9±4.28      | <0.001 |
| No. of large follicles                         | 8.2±4.44               | 12.0±6.12     | <0.001 |
| No. of oocytes retrieved                       | 8.3±4.52               | 12.0±6.48     | <0.001 |
| Zona abnormalities (%)                         | 30 (24.39%)            | 150 (27.68%)  | 0.450  |
| Polar body abnormalities (%)                   | 88 (71.55%)            | 446 (82.29%)  | 0.006  |
| No. of matured oocytes                         | 6.9±3.73               | 9.4±4.93      | <0.001 |
| No. of oocytes fertilized                      | 5.7±3.43               | 8.1±4.52      | <0.001 |
| No. of cleaved embryos                         | 5.8±3.41               | 8.1±3.53      | <0.001 |
| The endometrial thickness on the day of HCG (mm)| 8.9±1.39        | 8.79±1.29     | 0.443  |
| No. of women for whom embryo transfer was done| 99 (80.49%)            | 468 (86.35%)  | 0.090  |
The clinical pregnancy rate was relatively higher in the AMH category ≥1.10 (43.38% vs. 36.36%), but the difference was not statistically significant (p=0.199). The other outcomes, including fertilization rate (86.67±20.08 vs. 83.64±21.39) and live birth rate (25.85% vs. 22.22%, p=0.45) were also higher among the AMH category ≥1.10 group. However, none of the differences were statistically significant. When comparing the final pregnancy outcome, there was not much difference in the proportion between the categories (Table 2).

### Table 2. Comparison of fertility outcomes between AMH categories among women for whom embryo transfer was done (n=567)

| Parameters (%) | AMH category (Mean±SD) | P |
|----------------|------------------------|---|
|                | <1.10 (n=99)           | ≥1.10 (n=468) | |
| Fertilization  | 83.64±21.39            | 86.67±20.08  | 0.180 |
| Biochemical pregnancy | 3 (3.03%) | 18 (3.85%) | 1.000 |
| Clinical pregnancy | 36 (36.36%) | 203 (43.38%) | 0.199 |
| Abortion       | 6 (6.06%)              | 26 (5.56%)   | 0.843 |
| Live birth     | 22 (22.22%)            | 121 (25.85%) | 0.450 |

### Table 3. Determinants of clinical pregnancy (n=567)

| Model                  | Independent variables | AIC  | aOR (95% CI) | p-value |
|------------------------|-----------------------|------|--------------|---------|
| Complete model         |                       | 763.12 |              |         |
|                        | Wife's age (year)     | 0.98 (0.93-1.03) | 0.453 |
|                        | Husband's age (year)  | 1.01 (0.96-1.06) | 0.643 |
|                        | BMI of wife           | 0.98 (0.94-1.02) | 0.291 |
|                        | BMI of husband        | 1.01 (0.97-1.06) | 0.649 |
|                        | LH (mIU/L)            | 1.02 (0.98-1.07) | 0.344 |
|                        | FSH (mIU/ml)          | 1.00 (0.96-1.05) | 0.834 |
|                        | No. of large follicles| 1.01 (0.98-1.04) | 0.556 |
|                        | No. of oocytes retrieved | 0.99 (0.93-1.05) | 0.699 |
|                        | No. of matured oocytes | 0.93 (0.83-1.04) | 0.213 |
|                        | No. of fertilized oocytes | 1.26 (0.89-1.78) | 0.201 |
|                        | No. of cleaved embryos | 0.96 (0.68-1.36) | 0.812 |
|                        | AMH ≥1.10             | 1.00 (0.59-1.68) | 0.986 |

| Optimal model (lowest AIC value) | | |
| No. of matured oocytes | 0.92 (0.84-1.01) | 0.098 |
| No. of fertilized oocytes | 746.79 | 1.20 (1.09-1.33) | <0.001 |

In the complete model, the AIC value was 763.12. None of the predictors were found to be significant in the complete model (p>0.05). The optimal model was formed with two predictors (number of matured and fertilized oocytes). In the optimal model, the AIC value was 746.79. The number of oocytes fertilized was found to be a significant predictor in the optimal model. Regarding optimal model, for each number increase in fertilized oocytes, the probability of having clinical pregnancy is increased 1.20 times (aOR=1.20, 95%CI 1.09-1.33; p<0.001) (Table 3).

### Discussion

In IVF, embryologists are very keen on the assessment of oocyte and embryo quality. An oocyte ideally should have a clear, moderately granular cytoplasm, an intact first polar body, a small perivitelline space, and transparent zona pellucida. Prediction of oocyte competence and the selection methods proposed are still controversial and ineffective (7).

AMH is likely to be the best marker reflecting the decrease of ovarian reserve in the reproductive period compared to other ovarian tests. Hence, AMH in serum was considered to be a marker for embryo quality. Also, during IVF cycles, basal serum AMH concentrations can be used to detect ovarian response (11).
In the present study, wives' age (30.2±4.48) and husbands' age (35.45±4.68) were significantly less in >1.1 AMH group (p<0.001). Sowers et al. (12), in their study, reported that serum AMH levels decline with age. Similarly, Revelli et al. (13) confirmed that the probability of pregnancy was significantly affected by age and not by small differences in AMH level. When comparing the mean baseline parameters such as follicle-stimulating hormone values, number of large follicles, matured oocytes, fertilized oocytes, and cleaved embryos were statistically significant (p<0.001) among subjects with >1.1 AMH values. Weenen et al., in their study, reported that AMH was a superior marker for ovarian aging (4). In regularly cycling women, serum levels of AMH decrease over time, and there is a strong correlation between the number of antral follicles and AMH levels (5, 14). It is likely that the size of the recruited cohort of follicles is closely associated with the remaining primordial follicle pool. Due to depletion of the primordial follicle pool, post-menopausal women face decreased fertility. A similar study was reported by Irez et al. that AMH had a significantly negative correlation with woman age (p=0.018) and FSH (p=0.006) (8).

In the current study, assessment of AMH as a marker of ovarian response to FSH, the number of oocytes retrieved (12.14±6.48), number of matured oocytes (9.44±4.93), and number of fertilized oocytes (8.12±4.52) were greater in high-level AMH group (p<0.001). A study conducted by Seifer et al. demonstrated that higher AMH on day three of the stimulation protocol was associated with a higher number of retrieved oocytes. In particular, AMH levels were 2.5-fold higher in patients with at least 11 oocytes compared with those with six or fewer retrieved oocytes (1.0±0.4 vs. 2.5±0.3 ng/ml, p<0.0001) (15). Majumder et al. reported that AMH levels correlated with the number of good quality embryos available for transfer and the number of frozen embryos, but not with failed cleavage and fertilization rates (16). The similar results reported by Takahashi et al. showed that oocytes were more probable to be fertilized at high levels of AMH, as AMH levels in follicular fluid with fertilized oocytes were more than three times greater than the non-fertilized oocytes in follicles (17).

The number of cleaved embryos was higher in the >1.1 AMH group in the present study. In a study done by Lundin et al., a significantly higher proportion of good quality embryos resulted in early cleavage when compared with late cleavage (62.5 vs. 33.4%, p<0.0001). When examining day two and day three transfers, early-cleaving embryos (306 transfers) resulted in significantly greater rates of pregnancy/transfer (40.5 vs. 31.3%, p=0.0049), implantation (28.0 vs. 19.5%, p<0.0001), and birth/ongoing pregnancy rate (34.3 vs. 24.0%, p=0.0009) than late-cleaving embryos (18). This finding supports the hypothesis that implantation rates were associated with AMH levels.

Fertilization and clinical and biochemical pregnancy rates were 86.67±20.08, 18 (3.85%), and 203 (43.38%), respectively which are comparatively higher in subjects with >1.1 AMH levels but were not statistically significant in the present study. In line with the study of Hazout et al., greater AMH concentrations were associated with a higher number of mature oocytes, a higher number of embryos, followed by a greater clinical pregnancy rate (19). However, Cupisti et al. reported converse results stating that AMH levels in individual follicles were negatively correlated with developing and maturated oocytes (20). This can be elucidated by the fact that in IVF, to achieve a successful pregnancy, several additional factors, such as sperm parameters, male factor, endometrial receptivity, embryo development, and quality should be considered (21).

In the present study, embryo transfer was successful in 86.35% of cases at AMH levels greater than 1.1. When comparing the final pregnancy outcomes, singleton (66.67%) and triplets (1.82%) were more in ≥1.10 AMH level group, whereas more twins (37.93%) were reported in ≤1.10 AMH level group. Honnma et al. observed a significant association between serum AMH and day five embryo transfer (22). Kissin et al. reported that the number of transferred embryos, age, and stage of embryo transfer are important predictors of multiple gestations in assisted cycles (23). However, Tal et al. reported that serum AMH concentration is an independent predictor of twin pregnancy in fresh cycles in women aged 34 years and older (24).

The current study showed that with an increase in follicle-stimulating hormone, the probability of having AMH levels ≥1.10 decreased (aOR=0.76, 95%CI 0.58-0.99; p=0.044), and for each number increase in matured oocytes, the probability of AMH level ≥1.10 increased 2.44 times (aOR=2.44, 95%CI 1.01-5.87; p=0.047). The present study was in line with Singer et al.’ (25) research

**AMH Levels and Fertility Outcomes**
who reported a negative association between FSH and AMH serum levels in women undergoing IVF, concluding that the AMH level is highly predictive of the FSH level and can be used as an independent indicator of ovarian reserve. Furthermore, Dumesic et al. (26) also reported that intrafollicular AMH levels are negatively correlated with FSH in follicles of normoandrogenic ovulatory women undergoing IVF, concluding that intrafollicular AMH levels reflect the follicular sensitivity to FSH.

One of the main limitations of the study was that study population were all collected from a single center and only those visiting the fertility clinic were included which limits the generalizability of study findings. In fact, further research on the implication of varying AMH levels within the follicular fluid and other parameters like embryo quality, transfer technique, and endometrial receptivity on pregnancy outcomes needs to be investigated.

Conclusion

In conclusion, our results demonstrated that ≥1.10 serum AMH levels had a statistically significant more number of retrieved oocytes and good oocyte quality increased fertilization rates (p=0.180) and embryo transfer (p=0.09). AMH serum levels can serve as a novel marker for ovarian reserve and are associated with ovarian response in ART cycles. Further research should be carried out to produce multifactor prediction models by collecting larger datasets on AMH, FSH, AFC, and chronologic age which can be used clinically together to estimate pregnancy prospects.

Acknowledgement

We acknowledge the technical support in data entry, analysis and manuscript editing by "Evidencia Research Associates".

Conflict of Interest

There is no conflict of interest.

References

1. Chen C, Kattera S. Comparison of pronuclear zygote morphology and early cleavage status of zygotes as additional criteria in the selection of day 3 embryos: a randomized study. Fertil Steril. 2006;85 (2):347-52.
2. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113-30.
3. Josso N. Anti-müllerian hormone: hormone or growth factor? Prog Growth Factor Res. 1990;2(3):169-79.
4. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77-83.
5. de Vet A, Laven JS, de Jong FH,Themmen AP, Fauser BC. Anti-müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357-62.
6. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-müllerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005;45(1):20-4.
7. Penarrubia J, Fábregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment. Hum Reprod Update. 2005;20(4):915-22.
8. Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S. Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet. 2011;284(5):1295-301.
9. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007;14(5):602-10.
10. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009;92(5):1586-93.
11. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21(8):2022-6.
12. Sowers M, McConnell D, Gast K, Zheng H, Nan B, McCarthy JD, et al. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril. 2010;94(4):1482-6.
13. Revelli A, Biasoni V, Gennarelli G, Canosa S, Dalmaso P, Benedetto C. IVF results in patients with very low serum AMH are significantly affected by chronological age. J Assist Reprod Genet. 2016;33 (5):603-9.
14. Van Rooij I, Broekmans F, Te Velde E, Fauser B, Bancsi L, De Jong F, et al. Serum anti-Müllerian
hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17(12):3065-71.

15. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011;95(2):747-50.

16. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol. 2010;150(2):166-70.

17. Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Isaka K. Anti-Müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril. 2008;89(3):586-91.

18. Lundin K, Bergh C, Hardarson T. Early embryo cleavage is a strong indicator of embryo quality in human IVF. Hum Reprod. 2001;16(12):2652-7.

19. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323-9.

20. Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, et al. Correlations between antimüllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res. 2007;12(12):604-8.

21. Van den Bergh MJ, Fahy-Deshe M, Hohl MK. Pronuclear zygote score following intracytoplasmic injection of hyaluronan-bound spermatozoa: a prospective randomized study. Reprod Biomed Online. 2009;19(6):796-801.

22. Honnmma H, Baba T, Sasaki M, Hashiba Y, Oguri H, Fukunaga T, et al. Serum anti-Mullerian hormone levels affect the rate of ongoing pregnancy after in vitro fertilization. Reprod Sci. 2013;20(1):51-9.

23. Kissin DM, Schieve LA, Reynolds MA. Multiple-birth risk associated with IVF and extended embryo culture: USA, 2001. Hum Reprod. 2005;20(8):2215-23.

24. Tal R, Seifer DB, Khanimov M, Schwartz E, Grazi RV, Malter HE. Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles. Reprod Biomed Online. 2013;26(4):360-7.

25. Singer T, Barad DH, Weghofer A, Gleicher N. Correlation of antimullerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril. 2009;91(6):2616-9.

26. Dumesic DA, Lesnick TG, Stassart JP, Ball GD, Wong A, Abbott DH. Intrafollicular antimullerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer. Fertil Steril. 2009;92(1):217-21.